Danaher Corp (DHR)

Industry Diagnostics & Research


This stock can be held in an Investment ISA and an Investment Account
Sell

$191.00

Buy

$197.78

arrow-up$5.16 (+2.70%)

Prices updated at 17 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

Income statement

20232024
23,890m23,875m
14,034m14,206m
5,202m4,863m
21.7720.37
4,764m3,899m
7,496m7,276m
Sales, General and administrative7,329m7,759m
Interest expenses286m278m
Provision for income taxes823m747m
Operating expenses8,832m9,343m
Income before taxes5,044m4,646m
Net income available to common shareholders4,743m3,899m
6.445.33
Net interest income17m-161m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)6.385.29
Free cash flow per share9.14536.7125
Book value/share70.896971.3378
Debt equity ratio0.3301990.332398

Balance sheet

20232024
Current assets13,937m9,497m
Current liabilities8,274m6,798m
Total capital70,193m65,043m
Total debt19,536m17,146m
Total equity53,486m49,543m
Total non current liabilities--
Loans16,707m15,500m
Total assets84,488m77,542m
Total liabilities--
Cash and cash equivalents5,864m2,078m
Common stock739m719m

Cash flow

20232024
Cash at beginning of period5,995m5,864m
Cash dividends paid-1,248m-768m
5,781m5,296m
Investments (gains) losses-7,081m-1,981m
5,864m2,078m
Net income--
7,164m6,688m
-1,383m-1,392m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.